Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study-Reference-Cited by-同舟云学术

Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study

Published:2019-05 Issue:11 Volume:120 Page:1033-1036
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Pinato David J.,Mauri Francesco A.,Spina Paolo,Cain Owen,Siddique Abdul,Goldin Robert,Victor Stephane,Pizio Corinna,Akarca Ayse U.,Boldorini Renzo L.,Mazzucchelli Luca,Black James R. M.,Shetty Shishir,Marafioti Teresa,Sharma Rohini

Funder

Academy of Medical Sciences

Cancer Research UK

Wellcome Trust

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-019-0466-x.pdf

Reference10 articles.

1. Flynn, M. J., Sayed, A. A., Sharma, R., Siddique, A. & Pinato, D. J. Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma. Hepatology. 69, 2258–2270 (2018). https://doi.org/10.1002/hep.30337 .

2. Kythreotou, A., Siddique, A., Mauri, F. A., Bower, M. & Pinato, D. J. Pd-L1. J. Clin. Pathol. 71, 189–194 (2017). https://doi.org/10.1136/jclinpath-2017-204853 .

3. McLaughlin, J., Han, G., Schalper, K. A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J. et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2, 46–54 (2016).

4. Sunshine, J. C., Nguyen, P. L., Kaunitz, G. J., Cottrell, T. R., Berry, S., Esandrio, J. et al. PD-L1 expression in melanoma: a quantitative immunohistochemical antibody comparison. Clin. Cancer Res. 23, 4938–4944 (2017).

5. Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K. et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project. J. Thorac. Oncol. 12, 208–222 (2017).

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma;Targeted Oncology;2024-09

2. Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma;Biomedicines;2024-08-07

3. Development of Mutated β-catenin Gene Signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC;JHEP Reports;2024-08

4. KK-LC-1, a biomarker for prognosis of immunotherapy for primary liver cancer;BMC Cancer;2024-07-07

5. CD276 Promotes an Inhibitory Tumor Microenvironment in Hepatocellular Carcinoma and is Associated with Poor Prognosis;Journal of Hepatocellular Carcinoma;2024-07